Thirty-day readmission rates following hospitalization for pediatric sickle cell crisis at freestanding children's hospitals: risk factors and hospital variation
- PMID: 21674766
- PMCID: PMC4581528
- DOI: 10.1002/pbc.23221
Thirty-day readmission rates following hospitalization for pediatric sickle cell crisis at freestanding children's hospitals: risk factors and hospital variation
Abstract
Background: Readmission within 30 days after hospitalization for sickle cell crisis was developed by The National Association of Children's Hospitals (NACHRI) to improve hospital quality, however, there have been few studies validating this.
Procedure: We performed a retrospective examination of 12,104 hospitalizations for sickle crisis from July 1, 2006 and December 31, 2008 at 33 freestanding children's hospitals in the Pediatric Health Information System (PHIS) database. Hospitalizations met NACHRI criteria; inpatient admission, APR DRG code 662, age < 18, discharge home, and length of stay within 2 SD of the mean. We describe 30-day readmission rates, identify factors associated with readmission accounting for patient-level clustering and compare unadjusted versus adjusted variation in readmission rates.
Results: We identified 4,762 patients with 12,104 qualifying hospitalizations (1-30 per patient). Two thousand seventy-four (17%) hospitalizations resulted in a readmission within 30 days. Significant factors associated with readmission were age (OR 1.06/year, P < 0.0001), inpatient use of steroids (OR 1.48, P = 0.01) admission for pain without other sickle complications (OR 1.52, P < 0.0001) and simple transfusion (OR 0.58, P = 0.0002). There was significant variation in readmission rates between hospitals, even after accounting for clustering by patient and hospital case mix.
Conclusions: In a sample of free-standing children's hospitals, 17% of hospitalizations for sickle cell crisis result in readmission within 30 days. Older patients, those treated with steroids and those admitted for pain are more likely to be readmitted; simple transfusion is protective. Even after adjusting for case mix substantial hospital variation remains, but specific hospital to hospital comparisons differ depending on the exact methods used.
Copyright © 2011 Wiley Periodicals, Inc.
Conflict of interest statement
Conflict of interest: Nothing to declare.
Figures
Similar articles
-
Clinical redesign using all patient refined diagnosis related groups.Pediatrics. 2004 Oct;114(4):965-9. doi: 10.1542/peds.2004-0650. Pediatrics. 2004. PMID: 15466092
-
Pediatric readmission prevalence and variability across hospitals.JAMA. 2013 Jan 23;309(4):372-80. doi: 10.1001/jama.2012.188351. JAMA. 2013. PMID: 23340639 Free PMC article.
-
Corticosteroids for acute chest syndrome in children with sickle cell disease: variation in use and association with length of stay and readmission.Am J Hematol. 2010 Jan;85(1):24-8. doi: 10.1002/ajh.21565. Am J Hematol. 2010. PMID: 19957348 Free PMC article.
-
Epidemiology of pediatric hospitalizations at general hospitals and freestanding children's hospitals in the United States.J Hosp Med. 2016 Nov;11(11):743-749. doi: 10.1002/jhm.2624. Epub 2016 Jul 4. J Hosp Med. 2016. PMID: 27373782 Free PMC article.
-
Corticosteroids and increased risk of readmission after acute chest syndrome in children with sickle cell disease.Pediatr Blood Cancer. 2008 May;50(5):1006-12. doi: 10.1002/pbc.21336. Pediatr Blood Cancer. 2008. PMID: 17849474 Free PMC article. Clinical Trial.
Cited by
-
Chronic automated red cell exchange therapy for sickle cell disease.Transfusion. 2024 Aug;64(8):1509-1519. doi: 10.1111/trf.17924. Epub 2024 Jul 14. Transfusion. 2024. PMID: 39003570
-
Expert consensus on the management of infusion-related reactions (IRRs) in patients with sickle cell disease (SCD) receiving crizanlizumab: a RAND/UCLA modified Delphi panel.Ann Hematol. 2024 Jun;103(6):1909-1917. doi: 10.1007/s00277-024-05736-6. Epub 2024 Apr 20. Ann Hematol. 2024. PMID: 38642304 Review.
-
Return visit rates after an emergency department discharge for children with sickle cell pain episodes.Pediatr Blood Cancer. 2023 Oct;70(10):e30553. doi: 10.1002/pbc.30553. Epub 2023 Jul 17. Pediatr Blood Cancer. 2023. PMID: 37458568 Free PMC article.
-
Development and Validation of an Integrated Suite of Prediction Models for All-Cause 30-Day Readmissions of Children and Adolescents Aged 0 to 18 Years.JAMA Netw Open. 2022 Nov 1;5(11):e2241513. doi: 10.1001/jamanetworkopen.2022.41513. JAMA Netw Open. 2022. PMID: 36367725 Free PMC article.
-
Effects of corticosteroids in patients with sickle cell disease and acute complications: a systematic review and meta-analysis.Haematologica. 2022 Aug 1;107(8):1914-1921. doi: 10.3324/haematol.2021.280105. Haematologica. 2022. PMID: 35021607 Free PMC article.
References
-
- Committee on Quality of Health Care in America, Institute of Medicine. Crossing the quality chasm: A new health system for the 21st century. Washington, DC: National Academy Press; 2001.
-
- CMS Targets Readmissions Through Payment, Audits: ‘Coaching’ Model Reduces Rates. [Accessed Oct 20, 2010];Report on Medicare Compliance. 2008 Jun 30; < http://www.cfmc.org/files/rmc063008.pdf>.
-
- Patient Protection and Affordable Care Act. Senate and House of Representatives of the United States of America. 2010 Mar 23;
-
- QualityNet. Readmission Measures Overview: Publicly reporting risk-standardized, 30-day readmission measures for AMI, HF and PN. [Accessed Oct 20, 2010];2010 Oct 20; < http://www.qualitynet.org/dcs/ContentServer?c=Page&pagename=QnetPublic%2...>.
-
- NQMC 2010. Asthma: Risk-adjusted rate of unplanned readmission following discharge for asthma. [Accessed Oct 20, 2010];2010 Oct 20; < http://www.qualitymeasures.ahrq.gov/content.aspx?id=15071&search=readmis...>.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
